E3 Ligase Platforms

Protein Modulation

Scientist

Dysregulated and/or mutated proteins are at the core of the development and progression of many human diseases. The levels of both normal and disease-associated proteins are controlled by the Ubiquitin Proteasome System (UPS) as a natural process the body uses to maintain normal function of the cell. Manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells, could alter the outcome of numerous diseases. This discovery has led to our intensive focus on developing drugs that modulate this class of previously hard-to-drug enzymes.

Positioned at the forefront of drug development for protein modulation, Nurix has leveraged its deep E3 ligase expertise to develop its DELigase platform to either inhibit ligases or harness ligases to control target protein levels.

The broad scope of Nurix’s DELigase platform, powered by proprietary DNA-Encoded Libraries and an expanded set of E3 ligases used in discovery, differentiates Nurix from other companies developing therapies that target protein degradation.

The Ubiquitin Proteasome System (UPS): Regulating the Body’s Cellular Protein Levels


  • The levels of both normal and disease-associated proteins are regulated by the ubiquitin system and its component E3 ligases to maintain normal function of the cell
  • Dysregulated and/or mutated proteins are at the core of the development and progression of many human diseases
  • Drugs that can modulate the ubiquitin system and its component E3 ligases to control protein levels could alter the outcome of many diseases

DELigaseTM Platform

DEL screening enables discovery of both harness and inhibitors of E3 ligases

Our highly dynamic and powerful DELigaseTM drug discovery platform expands the universe of E3 ligases, the key enzymes responsible for controlling protein levels, that can be harnessed for protein modulation therapies.


  • Nurix’s small molecule drug harnesses an E3 ligase to ubiquitinate disease-associated dysregulated proteins.
  • After ubiquitination, dysregulated proteins are degraded by the proteasome, leading to a reduction in target protein levels.
  • Nurix’s small molecule drug inhibits an E3 ligase to block the ubiquitination and subsequent degradation of a target protein, leading to an increase in target protein levels

The platform includes an internal DNA-encoded library (DEL) used to screen a portfolio of E3 ligases and other protein targets of interest. We are differentiated by the breadth and versatility of our platform, which enables us to inhibit or harness ligases to control protein levels.

Dysregulated and/or mutated proteins are at the core of the development and progression of many human diseases and controlled by the ubiquitin system as a natural process the body uses to maintain normal function of the cell.

Manipulation of the ubiquitin system and its component E3 ligases could alter the outcome of numerous diseases. This discovery has led to our intensive focus on developing drugs that modulate this previously “undruggable” class.

  • Nurix’s small molecule drug harnesses an E3 ligase to ubiquitinate disease-associated dysregulated proteins.
  • After ubiquitination, dysregulated proteins are degraded by the proteasome, leading to a reduction in target protein levels.
  • Nurix’s small molecule drug inhibits an E3 ligase to block the ubiquitination and subsequent degradation of a target protein, leading to an increase in target protein levels.